Inter-relationships Among Glucose, Brain, Gut Microbiota and MicroRNAs (IRONmiRNA).

Obesity Clinical Trial

— IRONmiRNA  

Official title:

Inter-relationships Among Iron Stores, the Gut Metagenome, Glucose Levels, and Different Cognitive Domains: the Role of Circulating MicroRNAs (IRONmiRNA Study).

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05345106
• Other study ID #: IRONmiRNA-2022.043
• Status: Recruiting
• Start date: March 28, 2022
• Est. completion date: December 12, 2024

Study information

• Verified date: March 2024
• Source: Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta
• Contact: José Manuel Fernández-Real, M.D., Ph.D.
• Phone: +34 972 94 02 00
• Email: jmfreal[@]idibgi.org
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The brain is a recognized target of iron deposition. This process is enhanced by the presence of obesity and hyperglycemia and impacts cognitive functions. There is evidence suggesting that the gut microbiota composition modulates this process. It has been proposed that microRNAs are mediators in the dialogue between the composition and functionality of the intestinal microbiota and increased iron deposition in the brain. The hypothesis is that circulating microRNAs are associated with parameters of cognitive dysfunction, gut microbiota, brain iron content, glucose levels, and physical activity in subjects with and without obesity. The study includes both a cross-sectional (comparison of subjects with and without obesity) and a longitudinal design (evaluation one year after weight loss induced by bariatric surgery or by diet in patients with obesity) to evaluate the associations between circulating microRNAs, continuous glucose monitoring, brain iron content (by magnetic resonance), cognitive function (by means of cognitive tests), physical activity (measured by activity and sleep tracker device) and the composition of the microbiota, evaluated by metagenomics.

Description:

Subjects and methods: A. Cross-sectional study: Patients with obesity previously scheduled at the Service of Endocrinology, Diabetes, and Nutrition (UDEN) of the Hospital "Dr. Josep Trueta" of Girona (Spain) will be recruited and studied. Subjects without obesity will also be recruited through a public announcement. A glycemia sensor will be inserted for ten days, as well as an activity and sleep tracker device (Fitbit) to record physical activity during this period of time. Interstitial subcutaneous glucose concentrations will be monitored on an outpatient basis for a period of time of 10 consecutive days using a glucose sensor validated by the Food and Drug Administration (Dexcom G6 ®). The sensor will be inserted on day 0 and it will retire on day 10 mid-morning. Glucose records will preferably be evaluated on days 2 to 9 to avoid the bias caused by the insertion and removal of the sensor, which prevents a sufficient stabilization of the monitoring system. The characteristic glycemic pattern of each patient will be calculated on average from the profiles obtained on days 2 to 9. At the end of the week, magnetic resonance imaging will be done to evaluate the iron content in the brain and parameters of "Diffusion Tensor Imaging" in different brain territories. Cognitive tests will be carried out, and feces and urine will be collected for the study of the microbiota. Additionally, blood samples will be collected for the extraction and purification of circulating RNA and then retrotranscription of circulating miRNAs and preamplification. The project will be carried out in subjects with obesity (20 men, 20 premenopausal women, and 20 women postmenopausal, Body mass index (BMI) > = 30kg/m2) and subjects without obesity, similar in age, sex, and menopausal status (20 men, 20 premenopausal women, and 20 postmenopausal women, BMI <30kg/m2). B. Longitudinal study: After one year of follow-up, in which, subjects with obesity will undergo conventional treatment (hypocaloric diet, and physical activity advice) or bariatric surgery for weight loss, a second visit will be carried out. For comparison, the same protocol of the cross-sectional study will be done again. See the information above. DATA COLLECTION OF SUBJECTS OF CROSS-SECTIONAL AND LONGITUDINAL STUDIES: 1. Subsidiary data: Age, sex, and birth date. 2. Clinical variables: - Weight - height, - body mass index - waist and hip perimeters - waist-to-hip ratio - blood pressure (systolic and diastolic) - fat mass and fat free-mass (bioelectric impedance and DEXA) - smoking status - alcohol intake - registry of usual medicines - personal history of blood transfusion and/or donation - a record of family history of obesity, cardiovascular events, and diabetes - psychiatric and eating disorder history. 3. Laboratory variables: 15cc of blood will be extracted from fasted subjects to determine the following variables using the usual routine techniques of the clinical laboratory: - hemogram - glucose - bilirubin - aspartate aminotransferase (AST/GOT) - alanine aminotransferase (ALT/GPT) - gamma-glutamyl transpeptidase (GGT) - urea - creatinine - uric acid - total proteins, - albumin - total cholesterol | HDL cholesterol | LDL cholesterol - triglycerides, - glycated hemoglobin (HbA1c) - ferritin | soluble transferrin receptor - ultrasensitive C reactive protein - erythrocyte sedimentation rate - lipopolysaccharide binding protein - free thyroxine (free T4) | thyroid stimulating hormone (TSH) | baseline cortisol -plasma insulin - inflammation markers | interleukin 6 (IL-6). An additional 15cc of blood (plasma-EDTA) will be extracted for further analyses. 4. Stool samples collection: A stool sample will be provided from each patient. The sample should be collected at home or in the hospital, sent to the laboratory within 4 hours from the collection, fragmented, and stored at -80ºC. Analysis of gut microbiota in stool: *Determination of bacterial DNA and mRNA and study of the LBP binding protein in the blood for the detection of bacterial translocation. LBP binding protein in the blood for the detection of bacterial translocation. Hiseq and Nextseq technology (qPCR and protein analysis (WB, ELISA), OMICS (RNAseq, 16S, Metabolomics, Metagenomics). 5. Urine sample collection: Necessary to determine alterations in the metabolic pathways involved in tryptophan metabolism, and to determine the role of the intestinal microbiota in these metabolic changes. 6. Magnetic Resonance Imaging: All MRI examinations will be performed on a 1.5-T scanner (Ingenia ®; Philips Medical Systems). First, a fluid-attenuated inversion recovery (FLAIR) sequence will be used to exclude subjects with preexisting brain lesions. Brain iron load will be assessed by means of R2* values. T2* relaxation data will be acquired with a multi-echo gradient-echo sequence with 10 equally spaced echoes (first echo=4.6ms; inter echo spacing=4.6ms; repetition time=1300ms). T2* will be calculated by fitting the single exponential terms to the signal decay curves of the respective multi-echo data.R2* values will be calculated as R2*=1/T2* and expressed as Hz. In addition, R2* values will be converted to μmol Fe/g units as previously validated on phantom tests. Brain iron images from control subjects will be normalized to a standard space using a template image for this purpose (EPI MNI template). Subsequently, all normalized images will be averaged for the determination of normal iron content. Normal values (mean and SD) will be also calculated for anatomical regions of interest using different atlas masks, addressing possible differences between gender and age. The brain iron comparison between control and obese subjects will be performed using voxel-based analysis. Obese-subject images will be normalized to a standard space. The normalized image will be compared to the normal population using t-test analysis with age and sex as co-variables. As a result, a parametric map will show individual differences in the iron deposition. Based on previous observational studies showing increased brain iron load at some specific regions and the evidence suggesting hippocampal and hypothalamic changes in association with obesity and insulin resistance, the statistical and image analyses will be focused on iron differences at the caudate, lenticular, thalamus, hypothalamus, hippocampus, and amygdala. 7. Neuropsychological examination: Different domains of cognition will be explored: memory (Test aprendizaje verbal-TAVEC, Rey-Osterrieth Complex Figure) attention, and executive function(WAIS-IV, Trail making test (Part A y B), Stroop test), social cognition(POFA and BFRT), language (animals). Furthermore, depression (PHQ9), anxiety (State-Trait Anxiety Inventory (STAI)), impulsivity (Impulsive Behavior Scale (UPPS-P)), sensitivity to punishment and reward (Sensitivity to Punishment and Sensitivity to Reward (SRSPQ)), food addiction (Yale Food Addiction Scale (YFAS II)), subjective well being, positive and negative affect (Positive and Negative Affect Schedule (PANAS)) will be explored through psychological tests. 8. Profile of circulating miRNAs - Circulating RNA extraction and purification: Plasma will be obtained by standard venipuncture and centrifugation using EDTA-coated Vacutainer tubes (Becton-Dickinson, Franklin Lakes, NJ). Plasma separation will be performed by double centrifugation using a laboratory centrifuge (Beckman J-6M Induction Drive Centrifuge, Beckman Instruments Inc). RNA extraction will be performed from an initial volume of 300 μL of plasma using the mirVana PARIS isolation kit (Applied Biosystems, Darmstadt, Germany). - Retrotranscription of circulating miRNAs and preamplification: A fixed volume of 3 μL of RNA solution from the 40 mL, eluate of the RNA isolate will be used as input for retrotranscription using the TaqMan miRNA reverse transcription kit (Life Technology, Darmstadt, Germany). Preamplification will be carried out using the TaqMan PreAmp Master Mix (Life Technology, Darmstadt, Germany). - Analysis of individual miRNAs by TaqMan hydrolysis probes: Gene expression will be assessed by real-time PCR using the LightCycler 480 real-time PCR system (Roche Diagnostics, Barcelona, Spain), using the appropriate TaqMan technology for the quantification of relative gene expression. The information will remain registered in a notebook and will be computerized in the database of the study. STATICAL METHODS: Sample size: There are no previous data showing expected differences for sample size estimation regarding glucose variability, physical activity, the composition of gut microbiota, and cognitive function. In a previous study, differences in brain iron content were observed in 20 obese vs. 20 nonobese subjects. Thus, the proposed sample size is at least 20 individuals per group, with balanced age and gender (pre-and postmenopausal women) representation. Statistical analyses: Firstly, normal distribution and homogeneity of variances will be tested. To determine differences between study groups, it will be used χ2 for categorical variables, unpaired Student's t-test in normal quantitative, and Mann-Whitney U test for non-normal quantitative variables. Nonparametric Spearman analysis will be used to determine the correlation between quantitative variables. The same tests will also be used to study differences before and after follow-up. The significant associations, whether positive or negative, will be explored more in-depth (simple and multivariate linear regression analyses). The microbiota composition will be analyzed and compared using R "ALDEx2". Bacterial species and functions associated with brain iron and circulating microRNAs will be identified using robust linear regression models as implemented in the R package (Limma R). Moreover, p-values will be adjusted for multiple comparisons using the R package "SGoF".Measures of glycemic variability will be calculated using Matlab software (R2018a).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 120
• Est. completion date: December 12, 2024
• Est. primary completion date: December 12, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 30 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Men and women aged 30-65 years.

2. Informed consent for participation in the study.

Exclusion Criteria:

1. Serious systemic disease unrelated to obesity such as cancer, severe kidney, or liver disease, known type 1 or type 2 diabetes.

2. Systemic diseases with intrinsic inflammatory activity such as rheumatoid arthritis, Crohn's disease, asthma, chronic infection (e.g., HIV, active tuberculosis) or any type of infectious disease.

3. Pregnancy and lactation.

4. Patients with severe disorders of eating behaviour.

5. Persons whose liberty is under legal or administrative requirement.

6. Clinical symptoms and signs of infection in the previous month.

7. Antibiotic, antifungal or antiviral treatment in the previous 3 months.

8. Anti-inflammatory chronic treatment with steroidal and/or non-steroidal anti-inflammatory drugs.

9. Major psychiatric antecedents.

10. Excessive alcohol intake, either acute or chronic (alcohol intake greater than 40 g a day (women) or 80 g/day (men)) or drugs abuse.

11. Serum liver enzymes (AST, ALT) activity over twice the upper limit of normal.

12. History of disturbances in iron balance (e.g., genetic hemochromatosis, hemosiderosis from any cause, atransferrinemia, paroxysmal nocturnal hemoglobinuria).

Related Conditions & MeSH terms

• Obesity

Intervention

Procedure:
• Bariatric Surgery
Subjects with obesity (N=60) will be undertaken a hypocaloric diet and a periodic follow up, also 30 of them will undergo bariatric surgery

Locations

Country	Name	City	State
Spain	Institut d'Investigació Biomèdica de Girona (IDIBGI)	Girona

Sponsors (1)

Lead Sponsor	Collaborator
Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta

Country where clinical trial is conducted

Spain, 

References & Publications (39)

Arnoriaga Rodriguez M, Blasco G, Coll C, Biarnes C, Contreras-Rodriguez O, Garre-Olmo J, Puig J, Gich J, Ricart W, Ramio-Torrenta L, Fernandez-Real JM. Glycated Hemoglobin, but not Insulin Sensitivity, is Associated with Memory in Subjects with Obesity. Obesity (Silver Spring). 2019 Jun;27(6):932-942. doi: 10.1002/oby.22457. Epub 2019 Apr 15. — View Citation

Arnoriaga-Rodriguez M, Mayneris-Perxachs J, Burokas A, Contreras-Rodriguez O, Blasco G, Coll C, Biarnes C, Miranda-Olivos R, Latorre J, Moreno-Navarrete JM, Castells-Nobau A, Sabater M, Palomo-Buitrago ME, Puig J, Pedraza S, Gich J, Perez-Brocal V, Ricart W, Moya A, Fernandez-Real X, Ramio-Torrenta L, Pamplona R, Sol J, Jove M, Portero-Otin M, Maldonado R, Fernandez-Real JM. Obesity Impairs Short-Term and Working Memory through Gut Microbial Metabolism of Aromatic Amino Acids. Cell Metab. 2020 Oct 6;32(4):548-560.e7. doi: 10.1016/j.cmet.2020.09.002. — View Citation

Arnoriaga-Rodriguez M, Mayneris-Perxachs J, Contreras-Rodriguez O, Burokas A, Ortega-Sanchez JA, Blasco G, Coll C, Biarnes C, Castells-Nobau A, Puig J, Garre-Olmo J, Ramos R, Pedraza S, Brugada R, Vilanova JC, Serena J, Barretina J, Gich J, Perez-Brocal V, Moya A, Fernandez-Real X, Ramio-Torrenta L, Pamplona R, Sol J, Jove M, Ricart W, Portero-Otin M, Maldonado R, Fernandez-Real JM. Obesity-associated deficits in inhibitory control are phenocopied to mice through gut microbiota changes in one-carbon and aromatic amino acids metabolic pathways. Gut. 2021 Dec;70(12):2283-2296. doi: 10.1136/gutjnl-2020-323371. Epub 2021 Jan 29. — View Citation

Blasco G, Moreno-Navarrete JM, Rivero M, Perez-Brocal V, Garre-Olmo J, Puig J, Daunis-I-Estadella P, Biarnes C, Gich J, Fernandez-Aranda F, Alberich-Bayarri A, Moya A, Pedraza S, Ricart W, Lopez M, Portero-Otin M, Fernandez-Real JM. The Gut Metagenome Changes in Parallel to Waist Circumference, Brain Iron Deposition, and Cognitive Function. J Clin Endocrinol Metab. 2017 Aug 1;102(8):2962-2973. doi: 10.1210/jc.2017-00133. — View Citation

Blasco G, Puig J, Daunis-I-Estadella J, Molina X, Xifra G, Fernandez-Aranda F, Pedraza S, Ricart W, Portero-Otin M, Fernandez-Real JM. Brain iron overload, insulin resistance, and cognitive performance in obese subjects: a preliminary MRI case-control study. Diabetes Care. 2014 Nov;37(11):3076-83. doi: 10.2337/dc14-0664. Epub 2014 Aug 14. — View Citation

Bocchio-Chiavetto L, Maffioletti E, Bettinsoli P, Giovannini C, Bignotti S, Tardito D, Corrada D, Milanesi L, Gennarelli M. Blood microRNA changes in depressed patients during antidepressant treatment. Eur Neuropsychopharmacol. 2013 Jul;23(7):602-11. doi: 10.1016/j.euroneuro.2012.06.013. Epub 2012 Aug 25. — View Citation

Chen JJ, Zeng BH, Li WW, Zhou CJ, Fan SH, Cheng K, Zeng L, Zheng P, Fang L, Wei H, Xie P. Effects of gut microbiota on the microRNA and mRNA expression in the hippocampus of mice. Behav Brain Res. 2017 Mar 30;322(Pt A):34-41. doi: 10.1016/j.bbr.2017.01.021. Epub 2017 Jan 16. — View Citation

Fernandez Real JM, Moreno-Navarrete JM, Manco M. Iron influences on the Gut-Brain axis and development of type 2 diabetes. Crit Rev Food Sci Nutr. 2019;59(3):443-449. doi: 10.1080/10408398.2017.1376616. Epub 2017 Oct 17. — View Citation

Fernandez-Real JM, Blasco G, Puig J, Moreno M, Xifra G, Sanchez-Gonzalez J, Maria Alustiza J, Pedraza S, Ricart W, Maria Moreno-Navarrete J. Adipose tissue R2* signal is increased in subjects with obesity: A preliminary MRI study. Obesity (Silver Spring). 2016 Feb;24(2):352-8. doi: 10.1002/oby.21347. Epub 2015 Dec 26. — View Citation

Fernandez-Real JM, Lopez-Bermejo A, Ricart W. Cross-talk between iron metabolism and diabetes. Diabetes. 2002 Aug;51(8):2348-54. doi: 10.2337/diabetes.51.8.2348. — View Citation

Fernandez-Real JM, Manco M. Effects of iron overload on chronic metabolic diseases. Lancet Diabetes Endocrinol. 2014 Jun;2(6):513-26. doi: 10.1016/S2213-8587(13)70174-8. Epub 2013 Dec 30. — View Citation

Fernandez-Real JM, Ricart-Engel W, Arroyo E, Balanca R, Casamitjana-Abella R, Cabrero D, Fernandez-Castaner M, Soler J. Serum ferritin as a component of the insulin resistance syndrome. Diabetes Care. 1998 Jan;21(1):62-8. doi: 10.2337/diacare.21.1.62. — View Citation

Finch C. Regulators of iron balance in humans. Blood. 1994 Sep 15;84(6):1697-702. No abstract available. — View Citation

Foster JA, Lyte M, Meyer E, Cryan JF. Gut Microbiota and Brain Function: An Evolving Field in Neuroscience. Int J Neuropsychopharmacol. 2016 Apr 29;19(5):pyv114. doi: 10.1093/ijnp/pyv114. Print 2016 May. — View Citation

Geijselaers SLC, Sep SJS, Stehouwer CDA, Biessels GJ. Glucose regulation, cognition, and brain MRI in type 2 diabetes: a systematic review. Lancet Diabetes Endocrinol. 2015 Jan;3(1):75-89. doi: 10.1016/S2213-8587(14)70148-2. Epub 2014 Aug 24. Erratum In: Lancet Diabetes Endocrinol. 2015 Jan;3(1):e1. — View Citation

Griggs EM, Young EJ, Rumbaugh G, Miller CA. MicroRNA-182 regulates amygdala-dependent memory formation. J Neurosci. 2013 Jan 23;33(4):1734-40. doi: 10.1523/JNEUROSCI.2873-12.2013. — View Citation

Haramati S, Navon I, Issler O, Ezra-Nevo G, Gil S, Zwang R, Hornstein E, Chen A. MicroRNA as repressors of stress-induced anxiety: the case of amygdalar miR-34. J Neurosci. 2011 Oct 5;31(40):14191-203. doi: 10.1523/JNEUROSCI.1673-11.2011. — View Citation

Hoban AE, Stilling RM, M Moloney G, Moloney RD, Shanahan F, Dinan TG, Cryan JF, Clarke G. Microbial regulation of microRNA expression in the amygdala and prefrontal cortex. Microbiome. 2017 Aug 25;5(1):102. doi: 10.1186/s40168-017-0321-3. — View Citation

Horne R, St Pierre J, Odeh S, Surette M, Foster JA. Microbe and host interaction in gastrointestinal homeostasis. Psychopharmacology (Berl). 2019 May;236(5):1623-1640. doi: 10.1007/s00213-019-05218-y. Epub 2019 Mar 21. — View Citation

Kang SS, Jeraldo PR, Kurti A, Miller ME, Cook MD, Whitlock K, Goldenfeld N, Woods JA, White BA, Chia N, Fryer JD. Diet and exercise orthogonally alter the gut microbiome and reveal independent associations with anxiety and cognition. Mol Neurodegener. 2014 Sep 13;9:36. doi: 10.1186/1750-1326-9-36. — View Citation

Kau AL, Ahern PP, Griffin NW, Goodman AL, Gordon JI. Human nutrition, the gut microbiome and the immune system. Nature. 2011 Jun 15;474(7351):327-36. doi: 10.1038/nature10213. — View Citation

Kharabian Masouleh S, Beyer F, Lampe L, Loeffler M, Luck T, Riedel-Heller SG, Schroeter ML, Stumvoll M, Villringer A, Witte AV. Gray matter structural networks are associated with cardiovascular risk factors in healthy older adults. J Cereb Blood Flow Metab. 2018 Feb;38(2):360-372. doi: 10.1177/0271678X17729111. Epub 2017 Aug 31. — View Citation

Liu S, da Cunha AP, Rezende RM, Cialic R, Wei Z, Bry L, Comstock LE, Gandhi R, Weiner HL. The Host Shapes the Gut Microbiota via Fecal MicroRNA. Cell Host Microbe. 2016 Jan 13;19(1):32-43. doi: 10.1016/j.chom.2015.12.005. — View Citation

Lukiw WJ, Pogue AI. Induction of specific micro RNA (miRNA) species by ROS-generating metal sulfates in primary human brain cells. J Inorg Biochem. 2007 Sep;101(9):1265-9. doi: 10.1016/j.jinorgbio.2007.06.004. Epub 2007 Jun 13. — View Citation

Marden JR, Mayeda ER, Tchetgen Tchetgen EJ, Kawachi I, Glymour MM. High Hemoglobin A1c and Diabetes Predict Memory Decline in the Health and Retirement Study. Alzheimer Dis Assoc Disord. 2017 Jan-Mar;31(1):48-54. doi: 10.1097/WAD.0000000000000182. — View Citation

Moloney GM, Dinan TG, Clarke G, Cryan JF. Microbial regulation of microRNA expression in the brain-gut axis. Curr Opin Pharmacol. 2019 Oct;48:120-126. doi: 10.1016/j.coph.2019.08.005. Epub 2019 Oct 4. — View Citation

Moloney GM, O'Leary OF, Salvo-Romero E, Desbonnet L, Shanahan F, Dinan TG, Clarke G, Cryan JF. Microbial regulation of hippocampal miRNA expression: Implications for transcription of kynurenine pathway enzymes. Behav Brain Res. 2017 Sep 15;334:50-54. doi: 10.1016/j.bbr.2017.07.026. Epub 2017 Jul 20. — View Citation

Moreno-Navarrete JM, Blasco G, Xifra G, Karczewska-Kupczewska M, Stefanowicz M, Matulewicz N, Puig J, Ortega F, Ricart W, Straczkowski M, Fernandez-Real JM. Obesity Is Associated With Gene Expression and Imaging Markers of Iron Accumulation in Skeletal Muscle. J Clin Endocrinol Metab. 2016 Mar;101(3):1282-9. doi: 10.1210/jc.2015-3303. Epub 2016 Jan 14. — View Citation

Moreno-Navarrete JM, Moreno M, Puig J, Blasco G, Ortega F, Xifra G, Ricart W, Fernandez-Real JM. Hepatic iron content is independently associated with serum hepcidin levels in subjects with obesity. Clin Nutr. 2017 Oct;36(5):1434-1439. doi: 10.1016/j.clnu.2016.09.022. Epub 2016 Sep 29. — View Citation

Moreno-Navarrete JM, Rodriguez A, Becerril S, Valenti V, Salvador J, Fruhbeck G, Fernandez-Real JM. Increased Small Intestine Expression of Non-Heme Iron Transporters in Morbidly Obese Patients With Newly Diagnosed Type 2 Diabetes. Mol Nutr Food Res. 2018 Jan;62(2). doi: 10.1002/mnfr.201700301. Epub 2017 Dec 29. — View Citation

Ortega FJ, Mercader JM, Catalan V, Moreno-Navarrete JM, Pueyo N, Sabater M, Gomez-Ambrosi J, Anglada R, Fernandez-Formoso JA, Ricart W, Fruhbeck G, Fernandez-Real JM. Targeting the circulating microRNA signature of obesity. Clin Chem. 2013 May;59(5):781-92. doi: 10.1373/clinchem.2012.195776. Epub 2013 Feb 8. — View Citation

Ortega FJ, Mercader JM, Moreno-Navarrete JM, Rovira O, Guerra E, Esteve E, Xifra G, Martinez C, Ricart W, Rieusset J, Rome S, Karczewska-Kupczewska M, Straczkowski M, Fernandez-Real JM. Profiling of circulating microRNAs reveals common microRNAs linked to type 2 diabetes that change with insulin sensitization. Diabetes Care. 2014;37(5):1375-83. doi: 10.2337/dc13-1847. Epub 2014 Jan 29. — View Citation

Pedersen HK, Gudmundsdottir V, Nielsen HB, Hyotylainen T, Nielsen T, Jensen BA, Forslund K, Hildebrand F, Prifti E, Falony G, Le Chatelier E, Levenez F, Dore J, Mattila I, Plichta DR, Poho P, Hellgren LI, Arumugam M, Sunagawa S, Vieira-Silva S, Jorgensen T, Holm JB, Trost K; MetaHIT Consortium; Kristiansen K, Brix S, Raes J, Wang J, Hansen T, Bork P, Brunak S, Oresic M, Ehrlich SD, Pedersen O. Human gut microbes impact host serum metabolome and insulin sensitivity. Nature. 2016 Jul 21;535(7612):376-81. doi: 10.1038/nature18646. Epub 2016 Jul 13. — View Citation

Picao-Osorio J, Johnston J, Landgraf M, Berni J, Alonso CR. MicroRNA-encoded behavior in Drosophila. Science. 2015 Nov 13;350(6262):815-20. doi: 10.1126/science.aad0217. Epub 2015 Oct 22. — View Citation

Rolandsson O, Backestrom A, Eriksson S, Hallmans G, Nilsson LG. Increased glucose levels are associated with episodic memory in nondiabetic women. Diabetes. 2008 Feb;57(2):440-3. doi: 10.2337/db07-1215. Epub 2007 Oct 31. — View Citation

Ryan CM, Freed MI, Rood JA, Cobitz AR, Waterhouse BR, Strachan MW. Improving metabolic control leads to better working memory in adults with type 2 diabetes. Diabetes Care. 2006 Feb;29(2):345-51. doi: 10.2337/diacare.29.02.06.dc05-1626. — View Citation

Stilling RM, Moloney GM, Ryan FJ, Hoban AE, Bastiaanssen TF, Shanahan F, Clarke G, Claesson MJ, Dinan TG, Cryan JF. Social interaction-induced activation of RNA splicing in the amygdala of microbiome-deficient mice. Elife. 2018 May 29;7:e33070. doi: 10.7554/eLife.33070. — View Citation

Teng Y, Ren Y, Sayed M, Hu X, Lei C, Kumar A, Hutchins E, Mu J, Deng Z, Luo C, Sundaram K, Sriwastva MK, Zhang L, Hsieh M, Reiman R, Haribabu B, Yan J, Jala VR, Miller DM, Van Keuren-Jensen K, Merchant ML, McClain CJ, Park JW, Egilmez NK, Zhang HG. Plant-Derived Exosomal MicroRNAs Shape the Gut Microbiota. Cell Host Microbe. 2018 Nov 14;24(5):637-652.e8. doi: 10.1016/j.chom.2018.10.001. Epub 2018 Oct 25. — View Citation

Weinstein G, Maillard P, Himali JJ, Beiser AS, Au R, Wolf PA, Seshadri S, DeCarli C. Glucose indices are associated with cognitive and structural brain measures in young adults. Neurology. 2015 Jun 9;84(23):2329-37. doi: 10.1212/WNL.0000000000001655. Epub 2015 May 6. — View Citation

* Note: There are 39 references in all — Click here to view all references

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Concentration of advanced glycation end products (AGE) receptor agonists.	Enzyme-linked immunosorbent assay (ELISA).	30 months
Primary	Glycemic variability.	Mean and standard deviation of glucose measures in mg/dL using a continuous glucose monitoring during 10 days.	30 months
Primary	The percentage of time in glucose target range (glucose level 100mg/dl-125mg/dl)		30 months
Primary	The glycaemic risk measured with low blood glucose index (LBGI)	Low blood glucose index (LBGI) is a parameter that quantifies the risk of glycaemic	30 months
Primary	The glycaemic risk measured with high blood glucose index (HBGI)	High blood glucose index (HBGI) is a parameter that quantifies the risk of glycaemic	30 months
Primary	The glycaemic variability measured with mean amplitude of glycaemic excursions (MAGE)	measured in mg/dl	30 months
Primary	Minutes light sleep	Mean and standard deviation of minutes light sleep measures by activity and sleep tracker device.	30 months
Primary	Minutes deep sleep	Mean and standard deviation of minutes deep sleep measures by activity and sleep tracker device.	30 months
Primary	Minutes rapid eye movement (REM)	Mean and standard deviation of minutes REM measures by activity and sleep tracker device.	30 months
Secondary	Effect on brain structure.	Brain structure will be assessed using magnetic resonance imaging.	30 months
Secondary	Effect on gut microbiota.	Gut microbiota will be analysed by metagenomics and metabolomics.	30 months
Secondary	Changes from baseline in circulating concentration of AGE receptor agonists and glycemic variability one year of follow-up after weight loss in association with changes in brain structure and gut microbiota.	Subjects with obesity will be undertaken conventional treatment or bariatric surgery for weight loss; controls will not undergo any additional measure.	30 months
Secondary	Anxiety state	It will be measured by State-Trate Anxiety Inventory (STAI).	30 months
Secondary	Audioverbal memory	It will be measured by California Verbal Learning Test (CVLT). Minimum/maximum scale values (0-16), where 16 is a better audioverbal memory.	30 months
Secondary	Visual memory	It will be measured by Rey-Osterrieth Complex Figure. Minimum/maximum scale values (0-36), where 36 is a better visual memory	30 months
Secondary	Depressive symptomatology	It will be measured by Patient Health Questionnaire-9 (PHQ-9). Minimum/maximum scale values (0-27), where = 20 is severe depression.	30 months
Secondary	Impulsivity	It will be measured by Impulsive Behavior Scale (UPPS-P). The test evaluates: Negative	30 months
Secondary	Food Addiction	It will be measured by Yale Food Addiction Scale.It is a symptom score from 0-11, based on the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria, for substance dependence. Food addiction is diagnosed if =3 symptoms are reported.	30 months
Secondary	Behavioral inhibition	It will be measured by Sensitivity to Punishment and Sensitivity to Reward (SPSRQ). The scale of sensitivity to punishment is related to the behavioral inhibition system. It is made up of two subscales of 24 items each, where the higher the score, the greater the sensitivity to punishment.	30 months
Secondary	Behavioral activation	It will be measured by Sensitivity to Punishment and Sensitivity to Reward (SPSRQ). The reward sensitivity scale is related to the behavioral activation system. It is made up of two subscales of 24 items each, where the higher the score, the greater the sensitivity to reward.	30 months
Secondary	Visoconstructive function	It will be measured by Rey-Osterrieth Complex Figure. Minimum/maximum scale values (0-36), where 36 is a better visoconstructive function.	30 months
Secondary	Selective and alternating attention	It will be measured by Trail making test (Part A y B).	30 months
Secondary	Attention and working memory	It will be measured by the Digits subtest of Wechsler Adult Intelligence Scales, Fourth Edition (WAIS-IV).	30 months
Secondary	Inhibition	It will be measured by Stroop Color-Word Test.	30 months
Secondary	Phonemic verbal fluency	It will be measured by PMR.	30 months
Secondary	Semantic verbal fluency	It will be measured by Animals test. The person must name as many animals as possible in 1 minute. The result is corrected by standard scores, according to age and level of education.	30 months
Secondary	Facial recognition	It will be measured by Picture of Facial Recognition Test (POFA).	30 months
Secondary	Emotion recognition	It will be measured by Benton Facial Recognition Test (BFRT).This test evaluates the recognition of the five basic emotions: happiness, sadness, surprise, disgust, and anger.	30 months
Secondary	Diffusion Tensor Imaging brain sequences	Diffusion Tensor Imaging was acquired at 1.5 T (Philips ingenia) using a single-shot spin echo sequence with echo-planar imaging (EPI), 50 contiguous slices, voxel size 2x2x2.5 mm3, TE/TR of 72/3581 ms/ms, a diffusion-weighting factor b = 800 s/mm2 and diffusion encoding along 32 directions.	30 months
Secondary	Brain iron accumulation	It will be assessed using magnetic resonance imaging using (R2*)	30 months
Secondary	Resting-state functional brain sequences	It will be assessed using magnetic resonance imaging (T2*-weighted echo-planar imaging). T2 * relaxation data will be acquired with a multi-echo gradient sequence with 10 equidistant echoes (first echo = 4.6ms; echo spacing = 4.6ms; repetition time = 1300ms). The value value of T2 * will be calculated by adjusting the simple exponential terms for the signal decay of the respective echo time values.	30 months
Secondary	Insulin resistance	It will be measured by HOMA	30 months
Secondary	Markers of chronic inflammation: C-reactive protein, IL-6, adiponectin and soluble, tumor necrosis factor-a receptor fractions.	Enzyme-linked immunosorbent assay (ELISA) and quantitative polymerase chain reaction (qPCR)	30 months
Secondary	Glycosylated hemoglobin (HbA1c) value	Glycosylated hemoglobin (HbA1c) in % or mmol/mol	30 months
Secondary	The percentage of time in hyperglycaemia (glucose level above 250 mg/dl)		30 months
Secondary	The percentage of time in hypoglycaemia (glucose level below 70mg/dl)		30 months
Secondary	The percentage of time in glucose range (glucose level below 100 mg/dl)		30 months
Secondary	The percentage of time in glucose range (glucose level between 126-139 mg/dl)		30 months
Secondary	The percentage of time in glucose range (glucose level between 140-199 mg/dl)		30 months
Secondary	The percentage of time in glucose range (glucose level above 200 mg/dl)		30 months
Secondary	Burned calories	Mean and standard deviation of burned calories measures by activity and sleep tracker device.	30 months
Secondary	Steps	Mean and standard deviation of steps measures by activity and sleep tracker device.	30 months
Secondary	Distance	Mean and standard deviation of distance measures by activity and sleep tracker device.	30 months
Secondary	Minutes null activity	Mean and standard deviation of minutes null activity measures by activity and sleep	30 months
Secondary	Minutes slight activity	Mean and standard deviation of minutes slight activity measures by activity and sleep	30 months
Secondary	Minutes mean activity	Mean and standard deviation of minutes mean activity measures by activity and sleep tracker device.	30 months
Secondary	Minutes high activity	Mean and standard deviation of minutes high activity measures by activity and sleep tracker device.	30 months
Secondary	Calories	Mean and standard deviation of calories measures by activity and sleep tracker device.	30 months
Secondary	Minutes asleep	Mean and standard deviation of minutes asleep measures by activity and sleep tracker	30 months
Secondary	Minutes awake	Mean and standard deviation of minutes awake measures by activity and sleep tracker	30 months
Secondary	Bed time	Mean and standard deviation of bed time measures by activity and sleep tracker device.	30 months
Secondary	Number time awake	Mean and standard deviation of number time awake measures by activity and sleep	30 months